Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
about
Progress in adjuvant chemotherapy for breast cancer: an overviewIn vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index.Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198.BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsNew in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples.Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test).
P2860
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
@ast
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
@en
type
label
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
@ast
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
@en
prefLabel
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
@ast
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
@en
P1433
P1476
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
@en
P2093
J A Sparano
P433
P577
1999-06-01T00:00:00Z